Corticosteroid-induced osteoporosis

International Journal of Fertility and Women's Medicine

Volumn 46, Issue 4, 2001, Pages 190-205

  Adachi, Jonathan D ^a  

^a ST JOSEPH S HOSPITAL   (Canada)

Author keywords

(Review article 126 references); Anabolic therapy; Bisphosphonates; Calcitonin; Calcium vitamin D; Diuretics (thiazides); Fluoride; HRT; Inflammatory diseases

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; CLODRONIC ACID; CORTICOSTEROID; ETIDRONIC ACID; FLUORIDE; PAMIDRONIC ACID; RISEDRONIC ACID; THIAZIDE DIURETIC AGENT; VITAMIN D;

ASTHMA; BONE ATROPHY; BONE DENSITY; CHRONIC LIVER DISEASE; COMPUTER ASSISTED TOMOGRAPHY; CORTICOSTEROID THERAPY; DRUG INDICATION; ENTERITIS; FEMALE; FRACTURE; HORMONE SUBSTITUTION; HUMAN; LONG TERM CARE; OSTEOPOROSIS; PATHOPHYSIOLOGY; PEMPHIGUS; POSTMENOPAUSE; PRIORITY JOURNAL; REVIEW; RHEUMATIC POLYMYALGIA; RHEUMATOID ARTHRITIS; RISK FACTOR; SYSTEMIC LUPUS ERYTHEMATOSUS; VASCULITIS;

ADRENAL CORTEX HORMONES; DRUG THERAPY; FEMALE; HUMANS; MALE; OSTEOPOROSIS;

EID: 0035412512     PISSN: 1534892X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (126)

1. Adachi JD, Bensen WG, Brown J, et al: Intermittent cyclical etidronate therapy in the prevention of corticosteroid-induced osteoporosis. N Engl J Med 337:382-387, 1997.
2. Saag K, Emkey R, Schnitzer TJ, et al: Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. N Engl J Med 339:292-299, 1998.
3. Jenkins EA, Walker-Bone KE, Wood A, et al: The prevention of corticosteroid induced osteoporosis with intermittent cyclical etidronate. Bone 20:103S, 1997.
4. Abitbol V, Roux C, Chaussade S, et al: Metabolic bone assessment in patients with inflammatory bowel disease. Gastroenterology 108:417-422, 1995.
5. Motley RJ, Crawley EO, Evans C, et al: Increased rate of spinal trabecular bone loss in patients with inflammatory bowel disease. Gut 29:1332-1336, 1988.
6. Roux C, Abitbol V, Chaussade S, et al: Bone loss in patients with inflammatory bowel disease: A prospective study. Osteoporosis Int 5:156-160, 1995.
7. Motley R, Clements D, Evans WD, et al: A four-year longitudinal study of bone loss in patients with inflammatory bowel disease. Bone Mineral 23:95-104, 1993.
8. Clements D, Motley RJ, Evans WD, et al: Longitudinal study of cortical bone loss in patients with inflammatory bowel disease. Scand J Gastroenterol 27:1055-1060, 1992.
9. Silvennoinen JA, Kartunnen TJ, Niemela SE, et al: A controlled study of bone mineral density in patients with inflammatory bowel disease. Gut 37:71-76, 1995.
10. Bernstein CN, Seeger LL, Sayre JW, et al: Decreased bone density in inflammatory bowel disease is related to corticosteroid use and not disease diagnosis. J Bone Miner Res 10:250-256, 1995.
11. Marystone JF, Barrett-Connor EL, Morton DJ: Inhaled and oral corticosteroids: Their effects on bone mineral density in older adults. Am J Public Health 85:1693-1695, 1995.
12. Adinoff AD, Hollister JR: Steroid induced fractures and bone loss in patients with asthma. N Engl J Med 309:265-268, 1983.
13. Bressot C, Meunier PJ, Chapuy MC, et al: Histomorphometric profile, pathophysiology and reversibility of corticosteroid induced osteoporosis. Met Bone Dis Rel Res 1:303-311, 1979.
14. Dempster DW, Arlot MA, Meunier PJ: Mean wall thickness and formation periods of trabecular bone packets in corticosteroid-induced osteoporosis. Calcif Tiss Int 61:173-192, 1983.
15. Ishida Y, Heersche JNM: Glucocorticoid-induced osteoporosis: Both in vivo and in vitro concentrations of glucocorticoids higher than physiological levels attenuate osteoblast differentiation. J Bone Miner Res 13:1822-1826, 1998.
16. Peck WA, Brand J, Miller I: Hydrocortisone-induced inhibition of protein synthesis and uridine incorporation in isolated bone cells in vitro. Proc Natl Acad Sci USA 57:1599-1606, 1967.
17. Caporali R, Gentile S, Caprotti M, et al: Serum osteocalcin (bone gla-protein) and steroid osteoporosis in rheumatoid arthritis. J Rheumatol 18:148-149, 1991.
18. Neilsen HK, Thomsen K, Eriksen EF, et al: The effects of high-dose glucocorticoid administration on serum bone gamma carboxyglutamic acid containing protein, serum alkaline phosphatase and vitamin D metabolites in normal subjects. Bone Miner 4:105-113, 1988.
19. Prummel MF, Wiersinga WM, Lips P, et al: The course of biochemical parameters of bone turnover during treatment with corticosteroids. J Clin Endocrinol Metab 72:382-386, 1991.
20. Kotowicz MA, Hall S, Hunder GG, et al: Relationship of glucocorticoid dosage to serum bone glaprotein concentration in patients with rheumatologic disorders. Arthritis Rheum 33:1487-1491, 1990.
21. Manolagas SC: Corticosteroids and fractures: A close encounter of the third cell kind. J Bone Miner Res 15:1001-1005, 2000.
22. Stellon AJ, Webb A, Compston JE: Bone histomorphometry and structure in corticosteroid treated chronic active hepatitis. Gut 29:378-384, 1988.
23. Jee WSS, Park HZ, Roberts WE, et al: Corticosteroid and bone. Am J Anatomy 129:477-479, 1970.
24. Fucik RF, Kukreja SC, Hargis GK, et al: Effect of glucocorticoids on function of the parathyroid glands in man. J Clin Endocrinol Metab 40:152-155, 1975.
25. Lukert BP, Adams JS: Calcium and phosphorus homeostasis in man: Effect of corticosteroids. Arch Intern Med 136:1249-1253, 1976.
26. Hahn TJ, Hahn BH: Osteopenia in patients with rheumatic diseases: Principles of diagnosis and therapy. Semin Arthritis Rheum 6:165-188, 1976.
27. Seeman E, Dumar R, Hunder GG, et al: Production, degradation and circulating levels of 1,25-dihydroxyvitamin D in health and chronic glucocorticoid excess. J Clin Invest 66:664-669, 1980.
28. Hahn TJ, Halstead LR, Baran DT: Effects of short-term glucocorticoid administration on intestinal calcium absorption and circulating vitamin D metabolite concentrations in man. J Clin Endocrinol Metab 52:111-115, 1981.
29. Klein RG, Arnaud SB, Gallagher JC, et al: Intestinal calcium absorption in exogenous hypercortisolism: role of 25-hydroxyvitamin D concentrations in patients receiving chronic corticosteroid therapy. J Lab Clin Med 60:253-259, 1971.
30. Kimberg DV, Baerg DV, Gershon E, et al: Effects of cortisone administration on the metabolism and localization of 25-hydroxycholecalciferol in the rat. J Clin Invest 50:1309-1321, 1971.
31. Suzuki Y, Ichikawa Y, Saito E, et al: Importance of increased urinary calcium excretion in the development of secondary hyperparathyroidism of patients under glucocorticoid therapy. Metabolism 32:151-156, 1983.
32. Need AG: Corticosteroid and osteoporosis. Aust N Z J Med 17:267-272, 1987.
33. Godschalk M, Levy J, Downs RW: Glucocorticoids decrease vitamin D receptor numbers and gene expression in human osteosarcoma cells. J Bone Miner Res 7:21-27, 1992.
34. Ho YV, Briganti EM, Duan Y, et al: Polymorphism of the vitamin D receptor gene and corticosteroid-related osteoporosis. Osteoporosis Int 9:134-138, 1999.
35. Sakakura M, Takebe K, Nakagawa S: Inhibition of luteinizing hormone secretion induced by synthetic LRH by long-term treatment with glucocorticoids in human subjects. J Clin Endocrinol Metab 40:774-779, 1975.
36. Luton JP, Thiebolt P, Valcke JC, et al: Reversible gonadotrophin deficiency in male Cushing's disease. J Clin Endocrinol Metab 45:488-495, 1977.
37. Hsueh AJ, Erickson GF: Glucocorticoid inhibition of FSH-induced estrogen production in cultured rat granulosa cells. Steroids 32:639-648, 1978.
38. Doerr P, Pirke KM: Cortisol-induced suppression of plasma testosterone in normal adult males. J Clin Endocrinol Metab 43:622-629, 1976.
39. Schaison G, Durand F, Nakagawa S: Effect of glucocorticoids on plasma testosterone in men. Acta Endocrinol (Copenh) 89:126-131, 1987.
40. Crilly RG, Cawood M, Marshall DH, et al: Hormonal status in normal, osteoporotic and corticosteroid-treated postmenopausal women. J R Soc Med 71:733-736, 1978.
41. Goulding A, Gold E: Effects of chronic prednisolone treatment on bone resorption and bone composition in intact and ovariectomized rats receiving β-estradiol. Endocrinology 122:482-487, 1988.
42. Hahn TJ, Boiseau VC, Avioli LV, et al: Effect of chronic corticosteroid administration on diaphyseal and metaphyseal bone mass. J Clin Endocrinol Metab 39274-39282, 1974.
43. Maldague B, Malghem J, Deuxchaisnes C: Radiologic aspects of glucocorticoid-induced bone disease. Adv Exp Med Biol 171:155-190, 1984.
44. Arden NK, Baker J, Hogg C, et al: The heritability of bone mineral density, ultrasound of the calcaneus and hip axis length: A study of postmenopausal twins. J Bone Miner Res 11:530-534, 1996.
45. Morrison D, Capewell S, Reynolds SP, et al: Testosterone levels during systemic and inhaled corticosteroid therapy. Respir Med 88:659-663, 1994.
46. Ross PD, Davis JW, Epstein RS, et al: Pre-existing fractures and bone mass predict vertebral fracture incidence in women. Ann Intern Med 114:919-923, 1991.
47. Kimble RB: Alcohol, cytokines, and estrogen in the control of bone remodeling. Alcohol Clin Exp Med 21:385-391, 1997.
48. Ernst E: Exercise for female osteoporosis. A systematic review of randomized clinical trials. Sports Med 25:359-368, 1998.
49. Egger P, Duggleby S, Hobbs R, et al: Cigarette smoking and bone mineral density in the elderly. J Epidemiol Community Health 50:47-50, 1996.
50. Neilsen HK, Charles P, Moskelide L: The effect of single oral doses of prednisone on the circadian rhythm of serum osteocalcin in normal subjects. J Clin Endocrinol Metab 67:1025-1030, 1988.
51. Garnero P, Weichung JS, Gineyts E, et al: Comparison of new biochemical markers of bone turnover in late postmenopausal osteoporotic women in response to alendronate treatment. J Clin Endocrinol Metab 79:1693-1700, 1994.
52. Lukert BP, Raisz LG: Glucocorticoid-induced osteoporosis: Pathogenesis and management. Ann Intern Med 112:352-364, 1990.
53. Seeman E, Wagner HW, Offord KP, et al: Differential effects of endocrine dysfunction on the axial and appendicular skeleton. J Clin Invest 69:1302-1309, 1982.
54. Adachi JD, Bensen WG, Bianchi F, et al: Vitamin D and calcium in the prevention of corticosteroid-induced osteoporosis: A three year follow-up. J Rheumatol 23:995-1000, 1996.
55. Marshall D, Johnell O, Wedel H: Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporosis fractures. Br Med J 312:1254-1259, 1996.
56. Luengo M, Picado C, Del Rio L, et al: Vertebral fractures in steroid dependent asthma and involution osteoporosis: A comparison study. Thorax 46:803-806, 1991.
57. Saito JK, Davis JW, Wasnich RD, et al: Users of low dose glucocorticoids have increased bone loss rates: a longitudinal study. Calcified Tissue Int 57:115-119, 1995.
58. Gennari C: Glucocorticoids and bone, in Peck WA (ed): Bone and Mineral/3. Amsterdam, Elsevier, pp 213-232, 1985.
59. Adachi JD, Bensen WG, Bell MJ, et al: Corticosteroid induced osteoporosis: Followup over 3 years, in Christiansen C, Overgaard K (eds): Osteoporosis 1990 (3), Third International Symposium on Osteoporosis. Copenhagen, Denmark, pp 1745-1747, 1990.
60. Josse R, Adachi JD, Chines AA, Pack S, Stephenson GF, for the Canadian CIO Research Group: Prevention of corticosteroid-induced osteoporosis with etidronate: one year follow-up with calcium only. Osteoporosis Int 8:108, 1998.
61. Saag K, Emkey R, Cividino A, et al: Effects of alendronate for two years on BMD and fractures in patients receiving glucocorticoids. Bone 23:S182, 1998.
62. Ruegsegger P, Medici TC, Anliker M: Corticosteroid-induced bone loss. A longitudinal study of alternate day therapy in patients with bronchial asthma using quantitative computed tomography. Eur J Clin Pharmacol 25:615-620, 1983.
63. Sambrook PN, Eisman JA, Champion GD, et al: Determinants of axial bone loss in rheumatoid arthritis. Arthritis Rheum 30:721-728, 1987.
64. Dykman TR, Gluck OS, Murphy WA, et al: Evaluation of factors associated with glucocorticoid-induced osteopenia in patients with rheumatic diseases. Arthritis Rheum 28:361-368, 1985.
65. Hough S, Teitelbaum SL, Bergfeld MA, et al: Isolated skeletal involvement in Cushing's syndrome; response to therapy. J Clin Endocrinol Metab 52:1033-1038, 1981.
66. Riggs BL, Jowsey J, Kelley PJ: Quantitative microradiographic study of bone remodelling in Cushing's syndrome. Metabolism 15:773-780, 1966.
67. Gluck OS, Murphy WA, Hahn TJ, et al: Bone loss in adults receiving alternate day glucocortoid therapy. Arthritis Rheum 24:892-898, 1981.
68. Walsh LJ, Wong WA, Pringle M, et al: Use of oral corticosteroids in the community and the prevention of secondary osteoporosis: A cross sectional study. Br Med J 313:344-346, 1996.
69. Peat ID, Healy S, Reid DM, et al: Steroid induced osteoporosis: An opportunity for prevention? Ann Rheum Dis 54:66-68, 1995.
70. Amin S, LaValley MP, Simms RW, et al: A meta-analysis ranking efficacy of treatments for corticosteroid-induced osteoporosis (CSOP). Arthritis Rheum 41:S137, 1998.
71. Roux C, Oriente P, Laan R, et al: Randomized trial of effect of cyclical etidronate in the prevention of corticosteroid-induced bone loss. J Clin Endocrinol Metab 83:1128-1133, 1998.
72. Mulder H, Struys A: Intermittent cyclical etidronate in the prevention of corticosteroid-induced bone loss. Br J Rheumatol 33:348-350, 1994.
73. Wolfhagen FHJ, van Buuren HR, den Ouden JW, et al: Cyclical etidronate in the prevention of bone loss in corticosteroid-treated primary biliary cirrhosis. J Hepatol 26:325-330, 1997.
74. Skingle SJ, Crisp AJ: Increased bone density in patients on steroids with etidronate. Lancet 344:543-544, 1994.
75. Boutsen Y, Jamart J, Essenlinckx W, et al: Primary prevention of glucocorticoid-induced osteoporosis with intermittent intravenous pamidronate: A randomized trial. Calcif Tissue Int 61:266-271, 1997.
76. Gonnelli S, Rottoli P, Cepollaro C, et al: Prevention of corticosteroid-induced osteoporosis with alendronate in sarcoid patients. Calcif Tiss Int 61:382-385, 1997.
77. Cohen S, Levy R, Keller M, et al: Risedronate prevents corticosteroid-induced bone loss and decreases the risk of vertebral fractures. Arthritis Rheum 41:S1376, 1998.
78. Nordborg E, Schaufelberger C, Andersson R, et al: The ineffectiveness of cyclical oral clodronate on bone mineral density in glucocorticoid treated patients with giant cell arteritis. J Intern Med 242:367-371, 1997.
79. Pitt P, Li F, Todd P, et al: A double blind placebo controlled study to determine the effects of intermittent cyclical etidronate on bone mineral density in patients on longterm oral corticosteroid treatment. Thorax 53:351-356, 1998.
80. Geusens P, Vanhoof J, Stalmans R, et al: Cyclic etidronate increases bone density in the spine and hip in postmenopausal women on chronic corticosteroid treatment. A double-blind controlled study. Bone 20:9S, 1997.
81. Worth H, Stammen D, Keck E: Therapy of steroid induced bone loss in adult asthmatics with calcium, vitamin D, and a diphosphonate. Am J Respir Crit Care Med 150:394-397, 1994.
82. Reid D, Cohen S, Pack S, et al: Risedronate reduces the incidence of vertebral fractures in patients on chronic corticosteroid therapy. Arthritis Rheum 41:S136, 1998.
83. Reid IR, King AR, Alexander CJ, et al: Prevention of steroid-induced osteoporosis with (3-amino-1-hydroxypropylidene)-1,1-bisphosphate (APD). Lancet 1:143-146, 1988.
84. Reid D, Cohen S, Pack S, et al: Risedronate is an effective and well-tolerated therapy in both the treatment and prevention of corticosteroid-induced osteoporosis. Bone 23:2402, 1998.
85. Adachi JD, Pack S, Chines AA: Intermittent etidronate and corticosteroid-induced osteoporosis. N Engl J Med 337:1921, 1997.
86. Lukert BP, Johnson BE, Robinson RG: Estrogen and progesterone replacement therapy reduces glucocorticoid-induced bone loss. J Bone Miner Res 7:1063-1069, 1992.
87. Hall GM, Daniels M, Doyle D, et al: Effect of hormone replacement therapy on bone mass in rheumatoid arthritis patients treated with and without steroids. Arthritis Rheum 37:1499-1505, 1994.
88. Delmas PD, Bjarnason NH, Mitlak BH, et al: Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. N Engl J Med 337:1641-1647, 1997.
89. Sambrook PN, Birmingham J, Kelly P, et al: Prevention of corticosteroid osteoporosis. A comparison of calcium, calcitriol and calcitonin. N Engl J Med 328:1747-1752, 1993.
90. Healy JH, Paget S, Williams-Russo P, et al: A randomized controlled trial of salmon calcitonin to prevent bone loss in corticosteroid treated temporal arteritis and polymyalgia rheumatica. Calcif Tissue Int 59:73-80, 1996.
91. Adachi JD, Steele M, Gordon M, et al: Salmon calcitonin nasal spray in the prevention of corticosteroid-induced osteoporosis. Br J Rheumatol 36:255-259, 1997.
92. Luengo M, Picado C, Del Rio L, et al: Treatment of steroid-induced osteopenia with calcitonin in corticosteroid-dependent asthma. A one-year follow-up study. Am Rev Respir Dis 142:104-107, 1990.
93. Luengo M, Pons F, Martinez de Osaba MJ, et al: Prevention of further bone mass loss by nasal calcitonin in patients on long term glucocorticoid therapy for asthma: A two year follow-up study. Thorax 49:1099-1102, 1994.
94. Ringe JD, Welzel D: Salmon calcitonin in the therapy of corticoid-induced osteoporosis. Eur J Clin Pharmacol 33:35-39, 1987.
95. Kotaniemi A, Piirainen H, Paimela L, et al: Is continuous intranasal salmon calcitonin effective in treating axial bone loss in patients with active rheumatoid arthritis receiving low dose glucocorticoid therapy? J Rheumatol 23:1875-1879, 1996.
96. Lems WF, Jacobs JW, Bijlsma JW, et al: Is addition of sodium fluoride to cyclical etidronate beneficial in the treatment of corticosteroid-induced osteoporosis? Ann Rheum Dis 56:357-363, 1997.
97. Lems WF, Jacobs JWG, Bijlsma JWJ, et al: Effect of sodium fluoride on the prevention of corticosteroid-induced osteoporosis. Osteoporosis Int 7:575-582, 1997.
98. Guaydier-Souquières G, Kotzi PO, Sabatier JP, et al: In corticosteroid-treated respiratory diseases, monofluorophosphate increases lumbar bone density: A double-masked randomized study. Osteoporosis Int 6:171-177, 1996.
99. Rizzoli R, Bonjour JP, Slosman DO, et al: Sodium monofluorophosphate increases vertebral bone mineral density in patients with corticosteroid-induced osteoporosis. Osteoporosis Int 5:39-46, 1995.
100. Lane NE, Sanchez S, Modin GW, et al: Parathyroid hormone treatment can reverse corticosteroid-induced osteoporosis. J Clin Invest 102:1627-1633, 1998.
101. Reid IR, Wattle DJ, Evans MC, et al: Testosterone therapy in glucocorticoid-treated men. Arch Intern Med 156:1173-1177, 1996.
102. Adami S, Fossaluzza V, Rossini M, et al: Prevention of corticosteroid-induced osteoporosis with nandrolone decanoate. Bone Miner 15:73-81, 1991.
103. Lane NE, Sanchez S, Modin GW, et al: Bone mass continues to increase at the hip after parathyroid treatment is discontinued in glucocorticoid-induced osteoporosis: Results of a randomized controlled clinical trial. J Bone Miner Res 15:944-951, 2000.
104. Bernstein CN, Seeger LL, Anton PA, et al: A randomized, placebo-controlled trial of calcium supplementation for decreased bone density in corticosteroid-using patients with inflammatory bowel disease: A pilot study. Alimentary Pharmacology & Therapeutics 10:777-786, 1996.
105. Reginster JY, Kuntz D, Verdickt W, et al: Prophylactic use of alfacalcidol in corticosteroid-induced osteoporosis. Osteoporosis Int 9:75-81, 1999.
106. 3 supplementation prevents bone loss in the spine secondary to low-dose corticosteroid in patients with rheumatoid arthritis. Ann Intern Med 125:961-968, 1996.
107. Bijlsma JW, Raymakers JA, Mosch C, et al: Effect of oral calcium and vitamin D on glucocorticoid-induced osteopenia. Clin Exp Rheumatol 6:113-119, 1998.
108. Dykman TR, Haralson KM, Gluck OS, et al: Effect of oral 1,25-dihydroxyvitamin D on glucocorticoid-induced osteopenia in patients with rheumatic diseases. Arthritis Rheum 27:1336-1343, 1984.
109. Adams JS, Wahl TO, Lukert BP: Effects of hydrochlorothiazide and dietary sodium restriction on calcium metabolism in corticosteroid treated patients. Metabolism 30:217-221, 1981.
110. Alon U, Costanzo LS, Chan JC: Additive hypocalciuric effects of amiloride and hydrochlorothiazide in patients treated with calcitriol. Miner Electrolyte Metab 10:379-386, 1984.
111. Laan RFJM, van de Putte LBA, van Reil PLCM, et al: Low-dose prednisone induces rapid reversible axial bone loss in patients with rheumatoid arthritis. A randomized, controlled study. Ann Intern Med 119:963-968, 1993.
112. Pearce G, Tabensky DA, Delmas PD, et al: Corticosteroid-induced bone loss in men. J Clin Endocrinol Metab 83:801-806, 1998.
113. Aman S, Hakala M, Silvennoinen J, et al: Low incidence of osteoporosis in a two year follow-up of early community based patients with rheumatoid arthritis. Scand J Rheumatol 27:188-193, 1998.
114. Kroger H, Honkanen R, Saarikoski S, et al: Decreased axial bone mineral density in perimenopausal women with rheumatoid arthritis - A population based study. Ann Rheum Dis 53:18-23, 1994.
115. Sambrook PN, Birmingham J, Kempler S, et al: Corticosteroid effects on proximal femur bone loss. J Bone Miner Res 5:1211-1216, 1990.
116. LoCascio V, Bonucci E, Imbimbo B, et al: Bone loss in response to long-term glucocorticoid therapy. Bone Miner 8:39-51, 1990.
117. Mckay LI, DuBois DC, Sun YN, et al: Corticosteroid effects in skeletal muscle: Gene induction/receptor autoregulation. Muscle Nerve 20:1318-1320, 1997.
118. Van Balkom RH, Zhan WZ, Prakash YS, et al: Corticosteroid effects on isotonic contractile properties of rat diaphragm muscle. J Appl Physiol 83:1062-1067, 1997.
119. Gibson JN, Poyser NL, Morrison WL, et al: Muscle protein synthesis in patients with rheumatoid arthritis: Effects of chronic corticosteroid therapy on prostaglandin F2 alpha availability. Eur J Clin Invest 21:406-412, 1991.
120. Danneskiold-Samsoe B, Grimby G: Isokinetic and isometric muscle strength in patients with rheumatoid arthritis. The relationship to clinical parameters and the influence of corticosteroids. Clin Rheumatol 5:459-467, 1986.
121. Danneskiold-Samsoe B, Grimby G: Muscle mor-phology and enzymes in proximal and distal muscle groups of lower limb from patients with corticosteroid treated rheumatoid arthritis: the relationship to maximal isokinetic muscle strength. Clin Sci 71:685-691, 1986.
122. Shaw JM, Snow CM: Weighted vest exercise improves indices of fall risk in older women. J Gerontol Biol Sci Med Sci 53:M53-M58, 1998.
123. Nelson ME, Fiatarone MA, Morganti CM, et al: Effects of high-intensity strength training on multiple risk factors for osteoporotic fractures. A randomized controlled trial. JAMA 272:1909-1914, 1994.
124. Hickson RC, Davis JR: Partial prevention of glucocorticoid-induced muscle atrophy by endurance training. Am J Physiol 241:E232, 1981.
125. Hickson RC, Kurowski TT, Andrews GH, et al: Glucocorticoid cytosol binding in exercise-induced sparing of muscle atrophy. J Appl Physiol 60:1413-1419, 1986.
126. Czerwinski SM, Kurowski TG, O'Neill TM, et al: Initiating regular exercise protects against muscle atrophy from glucocorticoids. J Appl Physiol 63:1504-1510, 1987.